| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Conservation of the group O, Rhesus D negative blood supply
|
Uhl, Lynne
|
|
|
4 |
5 |
p. e195-e196
|
artikel
|
| 2 |
Correction to Lancet Haematol 2017; 4: e202–17
|
|
|
|
4 |
5 |
p. e201
|
artikel
|
| 3 |
Correction to Lancet Haematol 2017: 4: e183–91
|
|
|
|
4 |
5 |
p. e201
|
artikel
|
| 4 |
Correction to Lancet Haematol 2017; 4: e154–55
|
|
|
|
4 |
5 |
p. e201
|
artikel
|
| 5 |
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
|
Larsen, Torben B
|
|
|
4 |
5 |
p. e237-e244
|
artikel
|
| 6 |
Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational study
|
Selleng, Kathleen
|
|
|
4 |
5 |
p. e218-e224
|
artikel
|
| 7 |
Global improvements in childhood leukaemia survival
|
The Lancet Haematology,
|
|
|
4 |
5 |
p. e192
|
artikel
|
| 8 |
Issues raised by the incidence and survival of childhood cancers
|
Autier, Philippe
|
|
|
4 |
5 |
p. e193-e194
|
artikel
|
| 9 |
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
|
Mesa, Ruben A
|
|
|
4 |
5 |
p. e225-e236
|
artikel
|
| 10 |
The lure and pitfalls of administrative health registers
|
Johnsen, Søren Paaske
|
|
|
4 |
5 |
p. e199-e200
|
artikel
|
| 11 |
What should be the endpoints of a symptomatic drug and its control?
|
Leone, Giuseppe
|
|
|
4 |
5 |
p. e197-e198
|
artikel
|
| 12 |
Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries
|
Bonaventure, Audrey
|
|
|
4 |
5 |
p. e202-e217
|
artikel
|
Tijdschrift beschrijving